NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
DESVENLAFAXINE (desvenlafaxine fumarate) by Fosun Pharma is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. First approved in 2014.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Desvenlafaxine fumarate is an oral extended-release SNRI (serotonin-norepinephrine reuptake inhibitor) approved in 2014. It treats major depressive disorder by potentiating serotonin and norepinephrine in the central nervous system through reuptake inhibition. The drug demonstrates linear, dose-proportional pharmacokinetics with steady-state achieved in 4-5 days and minimal drug-drug interaction liability.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%); team size and growth trajectory dependent on market retention strategies.
Mechanism of Action
unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). 12.2…
Worked on DESVENLAFAXINE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.